特発性膜性腎症 - 市場の洞察、疫学、市場予測：2032年

主要7ヶ国の特発性膜性腎症の市場規模は、2034年までに10億米ドルに達すると予想されます。EU4ヶ国と英国の中で、2023年の市場規模が最も大きいのはドイツで1,000万米ドルとなっています。日本は2034年までに7,000万米ドルに増加すると予想されます。

特発性膜性腎症（IMN）は、主にネフローゼ症候群と関連する糸球体疾患の有病型です。免疫系による糸球体への攻撃が特徴で、著しい蛋白尿、浮腫を引き起こし、腎不全に進行する可能性があります。この疾患は、自己免疫疾患や感染症などの様々な基礎疾患から生じることもあるが、同定可能な二次的原因が見つからない場合は「特発性」と呼ばれます。IMNは一般的に成人、特に中年男性に発症し、泡沫尿、下肢や腹部のむくみ、体液貯留による体重増加などの症状を呈します。

IMNの診断には、臨床評価と臨床検査の組み合わせが必要です。初期評価には通常、蛋白尿を検出するための尿検査が含まれ、蛋白尿はしばしばネフローゼ範囲（3.5g/日以上）にあります。血液検査では腎機能を評価し、ネフローゼ症候群によくみられる低アルブミン血症や脂質異常症の有無を調べます。確定診断は通常、腎生検によって行われ、糸球体に特徴的な変化（毛細血管壁に沿った免疫複合体の沈着など）が認められます。さらに、ホスホリパーゼA2レセプター（PLA2R）などに対する特異的抗体の血清学的検査は、原発性IMNと二次性IMNの鑑別に役立ち、さらなる管理戦略の指針となります。

現在のところ、特発性膜性腎症の特効薬はなく、治療は主に症状の管理と病状の進行予防に重点が置かれています。支持療法としては、浮腫を管理するために利尿薬を使用し、蛋白尿を減少させ腎機能を保護するためにアンジオテンシン変換酵素（ACE）阻害薬またはアンジオテンシンII受容体拮抗薬（ARB）を使用します。支持療法が不十分な場合は、免疫抑制療法が開始されます。これにはコルチコステロイド、シクロホスファミド、自己免疫反応に関与するB細胞を標的とするリツキシマブなどの新しい薬剤が含まれます。しかし、これらの治療の有効性は様々であり、重大な副作用を伴うこともあります。最近の研究から、B細胞を標的とする治療法は有望であり、IMN患者の予後を改善する可能性があることが示唆されています。

当レポートでは、主要7ヶ国における特発性膜性腎症市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 特発性膜性腎症（IMN）市場概要

第4章 調査手法

第5章 IMNのエグゼクティブサマリー

第6章 重要な出来事

第7章 疾患の背景と概要

• イントロダクション
• 兆候と症状
• 分類
• 原因
• 病態生理学
• バイオマーカー
• 診断
• 診断ガイドライン

第8章 治療と管理

第9章 疫学と患者人口

• 主な調査結果
• 前提と根拠：主要7ヶ国
• 主要7ヶ国における膜性腎症の総罹患症例数
• 主要7ヶ国における特発性膜性腎症の総罹患症例数
• 米国
• EU4ヶ国と英国
• 日本

第10章 患者動向

第11章 新たな治療法

第12章 市場分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 主要7ヶ国におけるIMNの総市場規模
• 主要7ヶ国におけるIMNの市場規模（治療別）
• 米国における市場規模
• EU4ヶ国と英国における市場規模
• 日本における市場規模

第13章 KOLの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

List of Tables

• Table 1: Summary of IMN, Market and Epidemiology (2020-2034)
• Table 2: Total Prevalent Cases of Membranous Nephropathy in the 7MM (2020-2034)
• Table 3: Total Prevalent Cases of IMN in the United States (2020-2034)
• Table 4: Antigen-specific cases of IMN in the United States (2020-2034)
• Table 5: Total Treated Cases of IMN in the United States (2020-2034)
• Table 6: Total Prevalent Cases of IMN in Japan (2020-2034)
• Table 7: Antigen-specific cases of IMN in Japan (2020-2034)
• Table 8: Total Treated Cases of IMN in Japan (2020-2034)
• Table 9: Key Cross Competition
• Table 10: SNP-ACTH (1-39) Gel, Clinical Trial Description, 2024
• Table 11: BRUKINSA (zanubrutinib), Clinical Trial Description, 2024
• Table 12: GBT-601, Clinical Trial Description, 2024
• Table 13: GBT-601, Clinical Trial Description, 2024
• Table 14: Key Market Forecast Assumption of IMN in the US
• Table 15: Key Market Forecast Assumption of IMN in EU4 and the UK
• Table 16: Key Market Forecast Assumption of IMN in Japan
• Table 17: Total Market Size of IMN in the 7MM, in USD million (2020-2034)
• Table 18: Market Size of IMN by Therapies in the 7MM, in USD million (2020-2034)
• Table 19: Total Market Size of IMN in the United States, in USD million (2020-2034)
• Table 20: Market Size of IMN by Therapies in the United States, in USD million (2020-2034)
• Table 21: Total Market Size of IMN in EU4 and the UK, in USD million (2020-2034)
• Table 22: Market Size of IMN by Therapies in EU4 and the UK, in USD million (2020-2034)
• Table 23: Total Market Size of IMN in Japan, in USD million (2020-2034)
• Table 24: Market Size of IMN by Therapies in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Causes of Membranous Nephropathy
• Figure 2: Overview of the Complement Cascade
• Figure 3: Molecular Pathogenesis of MN
• Figure 4: Diagnostic Algorithm
• Figure 5: Evaluation of Patients With MN for Associated Conditions
• Figure 6: Clinical Criteria for Assessing Risk of Progressive Loss of Kidney Function
• Figure 7: Causes of Membranous Nephropathy
• Figure 8: Risk-based Treatment of MN
• Figure 9: Immunologic Monitoring in MN After the Start of Therapy
• Figure 10: Management of Initial Relapse After Therapy in MN
• Figure 11: Management of Resistant Disease in MN
• Figure 12: Evaluation of a Kidney Transplant Recipient With MN
• Figure 13: Management of Children With MN
• Figure 14: Anticoagulant Therapy in Patients With MN
• Figure 15: Total Prevalent Cases of Membranous Nephropathy in the 7MM (2020-2034)
• Figure 16: Addressable Pool of Membranous Nephropathy in the 7MM (2020-2034)
• Figure 17: Total Prevalent Cases of Idiopathic Membranous Nephropathy in the 7MM (2020-2034)
• Figure 18: Addressable Pool of Idiopathic Membranous Nephropathy in the 7MM (2020-2034)
• Figure 19: Total Prevalent Cases of IMN in the United States (2020-2034)
• Figure 20: Addressable Pool of IMN in the United States (2020-2034)
• Figure 21: Antigen-specific cases of IMN in the United States (2020-2034)
• Figure 22: Total Treated Cases of IMN in the United States (2020-2034)
• Figure 23: Total Prevalent Cases of IMN in EU4 and the UK (2020-2034)
• Figure 24: Addressable Pool of IMN in EU4 and the UK (2020-2034)
• Figure 25: Antigen-specific Cases of IMN in EU4 and the UK (2020-2034)
• Figure 26: Total Treated Cases of IMN in EU4 and the UK (2020-2034)
• Figure 27: Total Prevalent Cases of IMN in Japan (2020-2034)
• Figure 28: Addressable Pool of IMN in Japan (2020-2034)
• Figure 29: Antigen-specific cases of IMN in Japan (2020-2034)
• Figure 30: Total Treated Cases of IMN in Japan (2020-2034)
• Figure 31: Total Market Size of IMN in the 7MM (2020-2034)
• Figure 32: Market Size of IMN by Therapies in the 7MM (2020-2034)
• Figure 33: Total Market Size of IMN in the United States (2020-2034)
• Figure 34: Market Size of IMN by Therapies in the United States (2020-2034)
• Figure 35: Total Market Size of IMN in EU4 and the UK (2020-2034)
• Figure 36: Market Size of IMN by Therapies in EU4 and the UK (2020-2034)
• Figure 37: Total Market Size of IMN in Japan (2020-2034)
• Figure 38: Market Size of IMN by Therapies in Japan (2020-2034)
• Figure 39: Health Technology Assessment
• Figure 40: Reimbursement Process in Germany
• Figure 41: Reimbursement Process in France
• Figure 42: Reimbursement Process in Italy
• Figure 43: Reimbursement Process in Spain
• Figure 44: Reimbursement Process in the United Kingdom
• Figure 45: Reimbursement Process in Japan

Key Highlights:

• Idiopathic Membranous Nephropathy (IMN) is a significant type of glomerular disease characterized by the presence of large amounts of protein in the urine (nephrotic syndrome) and is primarily an autoimmune condition.
• There is currently no specific approved drugs for IMN, and management typically focuses on supportive care.
• The market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness.
• In 2023, the United States accounts for the largest market size with ~USD 88 million in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• The market of IMN in the 7MM is expected to reach ~USD 1,000 million by 2034.
• The total prevalent population of IMN in the 7MM is estimated to be ~71,000 cases in 2023.
• In 2023, the US accounted for ~40% of all prevalent cases of IMN in the 7MM, while EU4 and the UK combined accounted for ~35%, and Japan contributed ~25%. This data highlights Japan as the second-largest contributor after US to IMN cases.
• Few emerging drugs in pipeline are TNT119, ALPN-303, MOR202, SNP-ACTH (1-39) Gel, GAZYVA, and others.
• In October 2023, Human Immunology Biosciences (HI-Bio) announced that the FDA granted Breakthrough Therapy designation (BTD) to felzartamab for the treatment of primary membranous nephropathy.
• In June 2023, the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) for corticotrophin (ACTH) porcine (synthetic), otherwise referred to as SNP-ACTH (1-39) gel for the treatment of primary membranous nephropathy (PMN) a rare kidney disease.
• In July 2024, Biogen completed its acquisition of Human Immunology Biosciences (HI-Bio). Prior to this, in June 2022, HI-Bio and MorphoSys AG had entered into an equity participation and licensing agreement, under which HI-Bio was tasked with developing and commercializing MorphoSys' anti-CD38 antibody, felzartamab.

DelveInsight's "Idiopathic Membranous Nephropathy (IMN) - Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Idiopathic Membranous Nephropathy (IMN), historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy (IMN) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Idiopathic Membranous Nephropathy (IMN) market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Idiopathic Membranous Nephropathy (IMN) market size from 2020 to 2034. The report also covers current Idiopathic Membranous Nephropathy (IMN) treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Idiopathic Membranous Nephropathy (IMN) Understanding and Treatment Algorithm

Idiopathic Membranous Nephropathy (IMN) Overview

Idiopathic Membranous Nephropathy (IMN) is a prevalent form of glomerular disease primarily associated with nephrotic syndrome. It is characterized by the immune system's attack on the glomeruli, leading to significant proteinuria, edema, and potential progression to renal failure. The condition is termed "idiopathic" when no identifiable secondary cause is found, although it can also arise from various underlying conditions, including autoimmune diseases and infections. IMN typically affects adults, particularly middle-aged men, and presents with symptoms such as frothy urine, swelling in the legs and abdomen, and weight gain due to fluid retention.

The diagnosis of IMN involves a combination of clinical evaluation and laboratory tests. Initial assessments typically include urine analysis to detect proteinuria, which is often in the nephrotic range (>3.5 g/day). Blood tests are conducted to evaluate kidney function and check for hypoalbuminemia and dyslipidemia, common in nephrotic syndrome. A definitive diagnosis is usually confirmed through a kidney biopsy, which reveals characteristic changes in the glomeruli, such as immune complex deposition along the capillary walls. Additionally, serological tests for specific antibodies, such as those against the phospholipase A2 receptor (PLA2R), can help differentiate primary IMN from secondary forms, guiding further management strategies.

Further details related to country-based variations in diagnosis are provided in the report

Idiopathic Membranous Nephropathy (IMN) Treatment

Currently, there is no specific cure for IMN, and treatment primarily focuses on managing symptoms and preventing disease progression. Supportive care includes the use of diuretics to manage edema and angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) to reduce proteinuria and protect kidney function. In cases where supportive measures are insufficient, immunosuppressive therapies may be initiated. These include corticosteroids, cyclophosphamide, and newer agents like rituximab, which targets B cells implicated in the autoimmune response. However, the effectiveness of these treatments can vary, and they may carry significant side effects. Recent studies suggest that targeting B cells may offer a promising therapeutic approach, potentially improving outcomes in patients with IMN.

Idiopathic Membranous Nephropathy (IMN) Epidemiology

The Idiopathic Membranous Nephropathy (IMN) epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Idiopathic Membranous Nephropathy (IMN) epidemiology is segmented with detailed insights into total prevalent cases, antigen-specific cases, total treated cases of Idiopathic Membranous Nephropathy (IMN).

• In 2023, the US accounted for ~40% of all prevalent cases of IMN in 7MM.
• Japan's data suggests a relatively stable trend in the prevalence of IMN over the forecasted period of 2024-2034.
• Germany had the highest prevalence of IMN among EU4 and the UK, accounting for ~30% of cases, followed by the UK with ~20%, in 2023.
• In 2023, the PLA2R-specific cases in EU4 and the UK contributed ~75% in the 7MM.

Idiopathic Membranous Nephropathy (IMN) Drug Chapter

The drug chapter segment of the Idiopathic Membranous Nephropathy (IMN) report encloses a detailed analysis of Idiopathic Membranous Nephropathy (IMN) marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the Idiopathic Membranous Nephropathy (IMN) pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Emerging Drugs

GAZYVA (obinutuzumab): Hoffmann-La Roche

GAZYVA (obinutuzumab) is a humanized and glycoengineered type II anti-CD20 monoclonal antibody with superior in vitro B-cell cytotoxicity than rituximab. Obinutuzumab is directed at a different epitope on CD20 than that recognized by rituximab and can evoke a greater B-cell apoptotic response.

Currently, the drug is in Phase III of development. Roche plans to file a regulatory application for obinutuzumab as a treatment option for membranous nephropathy in or after 2025.

SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

Cerium has formulated a synthetic porcine ACTH drug substance into a subcutaneous injectable drug product (SNP-ACTH [1-39] Gel). Similar to other synthetic long-acting ACTH products containing highly purified synthetic ACTH peptides, a quantifiable number of ACTH molecules present in a long-acting synthetic ACTH drug product is a clear advantage for optimizing the dosing required to achieve strong response rates in PMN.

The Company has completed its preclinical studies confirming the safety and potency of SNP-ACTH (1-39) Gel and a Phase I clinical trial in healthy subjects, further demonstrating its safety and tolerability. Cerium has engaged with the FDA on its Phase III trial design and outcome measures for a prospective, randomized superiority trial to determine if SNP-ACTH (1-39) Gel is superior to rituximab in inducing a durable remission of proteinuria as a first-line immunosuppressive treatment of moderate to high-risk PMN patients. Cerium is currently enrolling patients in its Phase III clinical trial.

Idiopathic Membranous Nephropathy (IMN) Market Outlook

Key players, such as Hoffmann-La Roche, HI-Bio, Cerium Pharmaceuticals, BeiGene and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Idiopathic Membranous Nephropathy (IMN).

• In the 7MM, MOR202 (felzartamab) is expected to garner the largest market revenue of ~USD 500 million by 2034.
• Among the EU4 and the UK, Germany accounted for the highest market size of ~USD 10 million in 2023.
• Japan is expected to increase to ~USD 70 million by 2034.
• In 2023, Rituximab generated a revenue of ~USD 50 million in the 7MM.

Idiopathic Membranous Nephropathy (IMN) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Further detailed analysis of emerging therapies drug uptake in the report...

Idiopathic Membranous Nephropathy (IMN) Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Idiopathic Membranous Nephropathy (IMN) emerging therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight's analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as University of Minnesota, UCL Centre for Nephrology, University of Washington, Hospital Gregorio Maranon, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of Idiopathic Membranous Nephropathy (IMN). This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated, one of the most important primary outcome measures is change in urinary protein and change in anti-phospholipase A2 receptor (PLA2R) auto-antibody.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Idiopathic Membranous Nephropathy (IMN), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Idiopathic Membranous Nephropathy (IMN) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Idiopathic Membranous Nephropathy (IMN) market.

Idiopathic Membranous Nephropathy (IMN) Report Insights

• Patient Population
• Therapeutic Approaches
• Idiopathic Membranous Nephropathy (IMN) Pipeline Analysis
• Idiopathic Membranous Nephropathy (IMN) Market Size and Trends
• Existing and future Market Opportunity

Idiopathic Membranous Nephropathy (IMN) Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Idiopathic Membranous Nephropathy (IMN) Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL's feedback on approved and emerging therapies
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Idiopathic Membranous Nephropathy (IMN) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What is the growth rate of the 7MM Idiopathic Membranous Nephropathy (IMN) treatment market?
• What was the Idiopathic Membranous Nephropathy (IMN) total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Idiopathic Membranous Nephropathy (IMN)?
• How many companies are developing therapies for the treatment of Idiopathic Membranous Nephropathy (IMN)?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Idiopathic Membranous Nephropathy (IMN) Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Idiopathic Membranous Nephropathy (IMN) Market Overview at a Glance

• 3.1. Market Share (%) Distribution of IMN by Therapies in 2023
• 3.2. Market Share (%) Distribution of IMN by Therapies in 2034

4. Methodology

5. Executive Summary of IMN

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Sign and Symptoms
• 7.3. Classification
• 7.4. Causes
• 7.5. Pathophysiology
• 7.6. Biomarkers
• 7.7. Diagnosis
• 7.8. Diagnostic Guidelines

8. Treatment and Management

• 8.1. Treatment Strategy
• 8.2. Treatment of secondary MN
• 8.3. Treatment Guidelines
  • 8.3.1. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationales: 7MM
• 9.3. Total Prevalent Cases of Membranous Nephropathy in the 7MM
• 9.4. Total Prevalent Cases of Idiopathic Membranous Nephropathy in the 7MM
• 9.5. The United States
  • 9.5.1. Total Prevalent Cases of IMN in the US
  • 9.5.2. Antigen-specific cases of IMN in the US
  • 9.5.3. Total Treated Cases of IMN in the US
• 9.6. EU4 and the UK
  • 9.6.1. Total Prevalent Cases of IMN in EU4 and the UK
  • 9.6.2. Antigen-specific Cases of IMN in EU4 and the UK
  • 9.6.3. Total Treated Cases of IMN in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total Prevalent Cases of IMN in Japan
  • 9.7.2. Antigen-specific cases of IMN in Japan
  • 9.7.3. Total Treated Cases of IMN in Japan

10. Patient Journey

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Developmental Activities
  • 11.2.4. Analyst View
• 11.3. BRUKINSA (zanubrutinib): BeiGene
  • 11.3.1. Product Description
  • 11.3.2. Clinical Developmental Activities
  • 11.3.3. Analyst View
• 11.4. GAZYVA (obinutuzumab): Hoffmann-La Roche
  • 11.4.1. Product Description
  • 11.4.2. Clinical Developmental Activities
  • 11.4.3. Analyst View
• 11.5. MOR202 (felzartamab): MorphoSys/Human Immunology Biosciences
  • 11.5.1. Product Description
  • 11.5.2. Other developmental activities
  • 11.5.3. Clinical Developmental Activities
  • 11.5.4. Safety and efficacy
  • 11.5.5. Analyst View

12. Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebate
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptake
• 12.5. Total Market Size of IMN in the 7MM
• 12.6. Market Size of IMN by Therapies in the 7MM
• 12.7. United States Market Size
  • 12.7.1. Total Market Size of IMN in the US
  • 12.7.2. Market Size of IMN by Therapies in the US
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of IMN in EU4 and the UK
  • 12.8.2. Market Size of IMN by Therapies in EU4 and the UK
• 12.9. Japan Market Size
  • 12.9.1. Total Market Size of IMN in Japan
  • 12.9.2. Market Size of IMN by Therapies in Japan

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer